Sanofi and Regeneron Published P-III Trial Results of Dupixent (dupilumab) for Atopic Dermatitis in The Lancet
Shots:
- The P-III trial evaluating the efficacy & safety of Dupixent added to SoC low-potency TCS vs TCS alone in 162 children aged 6mos. to 5yrs. with uncontrolled mod. to sev. AD
- The results showed an improvement in skin clearance & reduced overall disease severity and itch over TCS alone @16wks., improvement in measures of sleep quality and skin pain along with patient or caregiver-reported outcomes & health-related QoL, and a lower proportion of patients who needs rescue medications. The safety results were similar to the safety profile in patients aged ≥6yrs. with AD
- The regulatory submission of Dupixent is currently under EMA’s review. The therapy has been approved in the US for AD, asthma, CRSwNP or EoE
Ref: Sanofi| Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
